Roche Holding | ROG - Des Atouts





Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Alcon AG USD 31.56B 31M 2025-12
Almirall EUR 2.34B 29.21M 2025-12
Amgen USD 90.59B 445M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Bayer EUR 104.54B 331M 2025-12
Biogen USD 29.44B 232M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Eli Lilly USD 112.48B 2.46B 2025-12
Fresenius EUR 42.46B 1.14B 2025-09
Fresenius Medical Care EUR 31B 115.33M 2025-12
Galapagos EUR 3.41B 105.39M 2025-12
Genmab DKK 12.87B 5.85B 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
GRIFOLS EUR 19.71B 141.77M 2025-12
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Lonza CHF 18.97B 164M 2025-12
Merck EUR 51.53B 600M 2025-12
Merck USD 129.55B 12.02B 2025-09
Novartis USD 110.95B 3.66B 2025-12
Orion EUR 2.01B 262M 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Philips EUR 26.94B 605M 2025-12
Recordati EUR 5.3B 122.58M 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 126.81B 2.99B 2025-12
UCB EUR 18.16B 971M 2025-12